FDA Reinspecting Abbott Depakote ER Backup Facility After Warning Letter
Executive Summary
FDA is reinspecting Abbott's Abbott Park, Ill. manufacturing facility as a follow-up to a warning letter citing violations of good manufacturing practices
You may also be interested in...
Abbott Upgrading Texas Rx Plant Following GMP Warning Letter
Abbott is accelerating enhancement of the monitoring system validation program for manufacturing at its Austin, Tex. facility following receipt of an FDA warning letter
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials